The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | ESMO 2018 Congress
Videos  >  

Armored CAR T Cells in Multiple Myeloma

Eric Smith, MD, PhD
Published Online:10:26 PM, Mon November 5, 2018


Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of armored chimeric antigen receptor (CAR) T cells in multiple myeloma. 

At Memorial Sloan Kettering, armored CAR T cells are used to encode at least 2 genes, 1 being the CAR itself and the second being a gene that gives T cells an advantage. According to Smith, it could be a proinflammatory cytokine that make T cells better killers. It could also be a ligand that is expressed on the surface and interacts with other cells in the tumor microenvironment.

Smith says they are also getting CAR T cells to secrete an antibody fragment against what is suppressing them with a PD-1/PD-L1. Checkpoint blockade has been effective in other malignancies as well, Smith added.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.